|
Indications and Dosage
Intravenous
Malignant neoplasms of the prostate Adult: As fosfestrol Na: Initially, 600-1,200 mg daily by slow inj over 1 hr to be given for 5-10 days followed by 300 mg daily for 10-20 days. Maintenance: 300-600 mg, reduce gradually over few mth from 4 times wkly to once wkly dosing. Oral Malignant neoplasms of the prostate Adult: As fosfestrol Na: 360-480 mg tid. Maintenance: 120-240 mg tid; may gradually reduce to 240 mg daily.
|
|
Special Precautions
Patient w/ history of heart disease. Hepatic impairment. Pregnancy and lactation.
|
|
Adverse Reactions
Temporary burning sensation in the perineal region, pain at the site of bony metastases, fluid retention, nausea, arterial and venous thrombosis, breast enlargement in male, impotence, withdrawal bleeding, increased blood Ca level.
|
|
Action
Description:
Mechanism of Action: Fosfestrol inhibits the action of androgen on prostate gland and also hormone induced growth of cancer cells by competitively binding to the androgen receptors, forming a drug-receptor complex. |
|
Storage
Store at room temp.
|
|
MIMS Class
|
|
ATC Classification
L02AA04 - fosfestrol ; Belongs to the class of estrogens.
|
|
References
Buckingham R (ed). Fosfestrol . Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 18/04/2016.
|
Sign Out
